Swissport Boost Commitment to Safety Vision With Ideagen Partnership
NOTTINGHAM, England–(BUSINESS WIRE)–#EMEA—Swissport International, a leading provider of ground services and cargo handling for the aviation sector,... Read more.
OLYMPUS Long-Term Follow-Up Study Reports Nearly Four-Year Duration of Response in Subset of Patients with Low-Grade Upper Tract Urothelial Cancer Who Achieved a Complete Response to Initial JELMYTO Treatment
Data Presented at the 2025 American Urological Association Annual Meeting in Las Vegas, Nevada PRINCETON, N.J.–(BUSINESS WIRE)–UroGen Pharma Ltd. (Nasdaq:... Read more.
Phixius by Nacha Expands Bank Account Validation Coverage With ValidiFI
NEW ORLEANS–(BUSINESS WIRE)–Phixius by Nacha—a secure, peer-to-peer payment information network—announced today that ValidiFI is live on... Read more.
New Patient-Reported Outcomes from UGN-102 Clinical Trials Show the Investigational Treatment Did Not Adversely Affect Functionality, Symptom Burden, and Quality of Life in Patients with LG-IR-NMIBC
New analysis of patient-reported outcomes from the OPTIMA II, ATLAS and ENVISION studies of UGN-102 presented at the American Urological Association (AUA) 2025 Annual... Read more.
New Long-Term Follow-Up Data from OPTIMA II Study of UGN-102 Demonstrates Median Duration of Response of Two Years in Patients with LG-IR-NMIBC
Data Presented at the American Urological Association 2025 Annual Meeting in Las Vegas, Nevada PRINCETON, N.J.–(BUSINESS WIRE)–UroGen Pharma Ltd. (Nasdaq:... Read more.
GERN Deadline: Rosen Law Firm Urges Geron Corporation (NASDAQ: GERN) Stockholders to Contact the Firm for Information About Their Rights
NEW YORK–(BUSINESS WIRE)–Rosen Law Firm, a global investor rights law firm, reminds investors that a shareholder filed a class action on behalf of purchasers... Read more.
KEYTRUDA® (pembrolizumab) as Perioperative Treatment With Standard of Care (SOC) Adjuvant Therapy Significantly Improved Event-Free Survival Compared to SOC Alone in Patients With Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma
KEYNOTE-689 marks the first positive trial in more than two decades for patients with resected locally advanced head and neck squamous cell carcinoma (LA-HNSCC)... Read more.
FLNC Deadline: Rosen Law Firm Urges Fluence Energy, Inc. (NASDAQ: FLNC) Stockholders to Contact the Firm for Information About Their Rights
NEW YORK–(BUSINESS WIRE)–Rosen Law Firm, a global investor rights law firm, reminds investors that a shareholder filed a class action on behalf of purchasers... Read more.
RC Deadline: Rosen Law Firm Urges Ready Capital Corporation (NYSE: RC) Stockholders to Contact the Firm for Information About Their Rights
NEW YORK–(BUSINESS WIRE)–Rosen Law Firm, a global investor rights law firm, reminds investors that a shareholder filed a class action on behalf of purchasers... Read more.
Lead Plaintiff Deadline on May 12, 2025 for GERN Investors – Kessler Topaz Meltzer & Check, LLP Encourages Investors with Losses to Contact the Firm
RADNOR, Pa.–(BUSINESS WIRE)–#classaction–The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that securities... Read more.